Key facts
- This page summarizes AbbVie Inc.'s Form 3 filing for AbbVie Inc. (ABBV).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 11 Jul 2025, 18:20.
AbbVie Inc. - 01 Jul 2025 Form 3 Insider Report for AbbVie Inc. (ABBV)
- Reporting relationship
- EVP, Chief HR Officer
- Issuer ticker
- ABBV
- Reported as of
- 01 Jul 2025
- Net transaction value
- $0
- Reporting owner signature
- /s/ T.O. Odutayo, Attorney-in-Fact for Demetris D. Crum
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
AbbVie Inc. filed Form 3 for AbbVie Inc. (ABBV) on 11 Jul 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001551152
Primary reporting owner
AbbVie Inc.
- Relationship
- EVP, Chief HR Officer
- Address
- 1 NORTH WAUKEEGAN ROAD, NORTH CHICAGO
- Signature
- /s/ T.O. Odutayo, Attorney-in-Fact for Demetris D. Crum
- Signature date
- 11 Jul 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABBV
holding
Common stock, $0.01 par value
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 7,048
- Date
- 01 Jul 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABBV
holding
Derivative
Option (Right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Jul 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,043
- Exercise price
- $175.28
- Footnotes
- F2
ABBV
holding
Derivative
Option (Right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Jul 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,687
- Exercise price
- $192.86
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Includes 1,113 restricted stock units granted under the AbbVie Amended and Restated 2013 Incentive Stock Program. These restricted stock units vest in full on February 16, 2026, and include the right to have stock withheld for tax purposes.
Footnote F2
Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 1,681 shares on 2/15/2025, and will become exercisable as to 1,681 shares on 2/15/2026 and as to 1,681 shares on 2/16/2027.
Footnote F3
Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 1,563 shares on 2/13/2026, as to 1,562 shares on 2/13/2027 and as to 1,562 shares on 2/13/2028.
SEC remarks
This initial holding statement has been made for Demetris D. Crum using the Issuer's CIK codes in order to satisfy Form 3 filing requirements for newly appointed company officers. An amendment will be filed for Mr. Crum upon receipt of his CIK filer codes from the SEC. Exhibit 24 - Power of Attorney.